Do analysts recommend TCRT or KTTA?

Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 522.54%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, TCRT or KTTA?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is TCRT or KTTA more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Pasithea Therapeutics N/A -57.44% -53.61%

Which has better valuation and earnings, KTTA or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is KTTA or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Alterity Therapeutics N/A N/A N/A

Does the media prefer KTTA or ATHE?

In the previous week, Pasithea Therapeutics and Pasithea Therapeutics both had 3 articles in the media. Pasithea Therapeutics' average media sentiment score of 0.63 beat Alterity Therapeutics' score of 0.29 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, KTTA or DWTX?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is KTTA or DWTX more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Dogwood Therapeutics N/A -108.57% -30.28%

Does the media refer more to KTTA or DWTX?

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 3 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.63 beat Dogwood Therapeutics' score of 0.48 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IZTC or KTTA?

Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 522.54%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, IZTC or KTTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is IZTC or KTTA more profitable?

Invizyne Technologies' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Pasithea Therapeutics N/A -57.44% -53.61%

Does the media favor IZTC or KTTA?

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for Pasithea Therapeutics and 1 mentions for Invizyne Technologies. Pasithea Therapeutics' average media sentiment score of 0.63 beat Invizyne Technologies' score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invizyne Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pasithea Therapeutics (KTTA) Competitors

$0.48 -0.01 (-1.65%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$0.48 0.00 (-0.60%)

As of 04:01 AM Eastern

Compare

KTTA vs. TCRT, MGX, ATHE, DWTX, and IZTC

Should you buy Pasithea Therapeutics stock or one of its competitors? MarketBeat compares Pasithea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pasithea Therapeutics include Alaunos Therapeutics (TCRT), Metagenomi (MGX), Alterity Therapeutics (ATHE), Dogwood Therapeutics (DWTX), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry.

How does Pasithea Therapeutics compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Pasithea Therapeutics and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat Pasithea Therapeutics' score of 0.63 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Very Positive
Pasithea Therapeutics	Positive

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 522.54%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Alaunos Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Pasithea Therapeutics' return on equity of -57.44% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Summary

Pasithea Therapeutics beats Alaunos Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Metagenomi?

Pasithea Therapeutics (NASDAQ:KTTA) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Pasithea Therapeutics has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Metagenomi	$25.21M	1.97	-$87.87M	-$2.30	N/A

Pasithea Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 522.54%. Metagenomi has a consensus target price of $7.00, indicating a potential upside of 430.30%. Given Pasithea Therapeutics' higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Pasithea Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Metagenomi	-384.61%	-51.23%	-36.62%

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Metagenomi. MarketBeat recorded 3 mentions for Pasithea Therapeutics and 1 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.75 beat Pasithea Therapeutics' score of 0.63 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Overall Sentiment
Pasithea Therapeutics	Positive
Metagenomi	Positive

Pasithea Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

23.9% of Pasithea Therapeutics shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Metagenomi beats Pasithea Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Alterity Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Pasithea Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 522.54%. Alterity Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 158.45%. Given Pasithea Therapeutics' higher possible upside, equities analysts plainly believe Pasithea Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alterity Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Alterity Therapeutics	N/A	N/A	N/A

In the previous week, Pasithea Therapeutics and Pasithea Therapeutics both had 3 articles in the media. Pasithea Therapeutics' average media sentiment score of 0.63 beat Alterity Therapeutics' score of 0.29 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pasithea Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Alterity Therapeutics beats Pasithea Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Dogwood Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Pasithea Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 522.54%. Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 739.16%. Given Dogwood Therapeutics' higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Pasithea Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

Pasithea Therapeutics' return on equity of -57.44% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 3 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.63 beat Dogwood Therapeutics' score of 0.48 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Pasithea Therapeutics beats Dogwood Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for Pasithea Therapeutics and 1 mentions for Invizyne Technologies. Pasithea Therapeutics' average media sentiment score of 0.63 beat Invizyne Technologies' score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invizyne Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Invizyne Technologies' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Pasithea Therapeutics	N/A	-57.44%	-53.61%

23.9% of Pasithea Therapeutics shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 522.54%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Pasithea Therapeutics beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KTTA vs. The Competition

Export

Metric	Pasithea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.22M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.23	20.98	27.01	24.38
Price / Sales	N/A	311.10	519.43	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	0.20	8.54	10.80	6.33
Net Income	-$20.43M	$23.83M	$3.59B	$331.02M
7 Day Performance	-5.79%	-2.77%	-1.47%	-0.33%
1 Month Performance	-13.95%	5.85%	2.78%	-1.29%
1 Year Performance	-29.65%	52.15%	28.50%	21.30%

Pasithea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KTTA Pasithea Therapeutics	3.2945 of 5 stars	$0.48 -1.7%	$3.00 +522.5%	-30.2%	$12.22M	N/A	N/A	3
TCRT Alaunos Therapeutics	0.5743 of 5 stars	$2.07 +1.5%	N/A	-47.8%	$49.82M	N/A	N/A	40	Positive News High Trading Volume
MGX Metagenomi	2.8587 of 5 stars	$1.29 -2.3%	$7.00 +442.6%	-41.3%	$49.69M	$25.21M	N/A	236	Analyst Downgrade
ATHE Alterity Therapeutics	3.5411 of 5 stars	$5.58 +1.6%	$13.00 +133.0%	+8.6%	$48.68M	N/A	N/A	10	Positive News Gap Up
DWTX Dogwood Therapeutics	2.5435 of 5 stars	$1.41 -2.1%	$12.00 +751.1%	-71.9%	$48.43M	N/A	N/A	5	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KTTA) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. TCRT, MGX, ATHE, DWTX, and IZTC

How does Pasithea Therapeutics compare to Alaunos Therapeutics?

Summary

How does Pasithea Therapeutics compare to Metagenomi?

Summary

How does Pasithea Therapeutics compare to Alterity Therapeutics?

Summary

How does Pasithea Therapeutics compare to Dogwood Therapeutics?

Summary

How does Pasithea Therapeutics compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. TCRT, MGX, ATHE, DWTX, and IZTC

How does Pasithea Therapeutics compare to Alaunos Therapeutics?

Does the media refer more to TCRT or KTTA?

Which has stronger earnings and valuation, TCRT or KTTA?

Do analysts recommend TCRT or KTTA?

Do institutionals and insiders have more ownership in TCRT or KTTA?

Which has more volatility and risk, TCRT or KTTA?

Is TCRT or KTTA more profitable?

Summary

How does Pasithea Therapeutics compare to Metagenomi?

Which has preferable valuation & earnings, KTTA or MGX?

Do analysts prefer KTTA or MGX?

Is KTTA or MGX more profitable?

Does the media prefer KTTA or MGX?

Which has more volatility and risk, KTTA or MGX?

Do institutionals & insiders have more ownership in KTTA or MGX?

Summary

How does Pasithea Therapeutics compare to Alterity Therapeutics?

Do analysts recommend KTTA or ATHE?

Is KTTA or ATHE more profitable?

Does the media prefer KTTA or ATHE?

Which has more volatility & risk, KTTA or ATHE?

Which has better valuation and earnings, KTTA or ATHE?

Do institutionals & insiders hold more shares of KTTA or ATHE?

Summary

How does Pasithea Therapeutics compare to Dogwood Therapeutics?

Do analysts prefer KTTA or DWTX?

Which has higher earnings & valuation, KTTA or DWTX?

Which has more volatility & risk, KTTA or DWTX?

Is KTTA or DWTX more profitable?

Does the media refer more to KTTA or DWTX?

Do institutionals and insiders believe in KTTA or DWTX?

Summary

How does Pasithea Therapeutics compare to Invizyne Technologies?

Which has stronger earnings & valuation, IZTC or KTTA?

Does the media favor IZTC or KTTA?

Is IZTC or KTTA more profitable?

Do institutionals & insiders have more ownership in IZTC or KTTA?

Do analysts recommend IZTC or KTTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools